Showing 6811-6820 of 8649 results for "".
- Academic Settings in a Pandemic: Rules and Regulationshttps://modernod.com/news/academic-settings-in-a-pandemic-rules-and-regulations/2479507/
- CEO Expects Pfizer Will Know By October If COVID-19 Vaccine Workshttps://modernod.com/news/ceo-expects-pfizer-will-know-by-october-if-covid-19-vaccine-works/2478246/Pfizer CEO Albert Bourla said that late-stage study results could be available by the end of October for a coronavirus vaccine it is co-developing with BioNTech, adding “we should have enough [data]…to say whether the product works or not.” His remarks come in the wake of the Trump ad
- Nearly One Quarter of Chinese Children Hospitalized With COVID-19 Developed Eye Symptomshttps://modernod.com/news/nearly-one-quarter-of-chinese-children-hospitalized-with-covid-19-developed-eye-symptoms/2478244/Among Chinese children hospitalized for COVID-19, nearly a quarter developed ocular symptoms, a new study finds, Reuters reported. Most children developed eye symptoms later in the disease, but in nine, ocular manifestations were the first
- Sanofi, GSK Start Phase 1/2 Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/sanofi-gsk-start-phase-1-2-study-of-covid-19-vaccine-candidate/2478239/Sanofi and GlaxoSmithKline announced Thursday the start of a phase 1/2 study of their experimental adjuvanted COVID-19 vaccine, with plans to move to late-stage trials this year. The companies added that in parallel, they are scaling up manufacturing of the antigen and adjuvant with the target of
- Patient Comanagement and Referrals in the Age of COVID-19https://modernod.com/news/patient-comanagement-and-referrals-in-the-age-of-covid-19/2479508/
- Omeros Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19https://modernod.com/news/omeros-reports-recovery-and-survival-of-all-patients-in-study-evaluating-narsoplimab-for-treatment-of-covid-19/2478141/Omeros, maker of Omidria (phenylephrine and ketorolac intraocular solution 1%/0.3%) for use during cataract surgery to prevent miosis and reduce postoperative pain, reported the results of a compassionate-use study evaluating narso
- Johnson & Johnson Forges $1-Billion Pact to Supply US with COVID-19 Vaccinehttps://modernod.com/news/johnson-johnson-forges-1-billion-pact-to-supply-us-with-covid-19-vaccine/2478133/Johnson & Johnson said it entered into an agreement with the US government for the large-scale domestic manufacturing and delivery of 100 million doses of its investigational SARS-CoV-2 vaccine Ad26.COV2.S for use in the country. Specifically, the US Biomedical Advanced Research and Developme
- Vision Expo Introduces InFocus Video Serieshttps://modernod.com/news/vision-expo-introduces-infocus-video-series/2478114/Vision Expo announced the launch of InFocus, a series of 4-minute video interviews with some of Vision Expo’s top industry attendees and OPTImum program buyers conducted by Suzanne Krauss, OPTImum Program Manager at Vision Expo. The InFocus Series launches this week with a new video to be
- Face-to-Face Meetings Between Pharma and Doctors Are On the Uphttps://modernod.com/news/face-to-face-meetings-between-pharma-and-doctors-are-on-the-up/2478102/Second-quarter results reported to date by large-cap pharmaceutical and biotech companies illustrate that social distancing measures weighed heavily on topline drug revenues in April and May. In addition to slowing patient access to medicines, the COVID-19 pandemic has also forced the industry to
- As Ophthalmology Clinics Reopen, New Questions Aboundhttps://modernod.com/news/as-ophthalmology-clinics-reopen-new-questions-abound/2478093/As the COVID-19 pandemic continues to upend our professional and personal lives, predicting what the future may hold has become an increasingly difficult task. Sumit (Sam) Garg, MD, wrote a commentary for Medscape News discussing what the